A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer

PURPOSE: The primary objective of this phase I dose-escalation study was to identify the maximum tolerated dose (MTD) of sunitinib plus pemetrexed in patients with advanced cancer. METHODS: Using a 3 + 3 dose-escalation design, patients received oral sunitinib qd by continuous daily dosing (CDD sche...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, L. Q. M., Blais, N., Jonker, D. J., Laurie, S. A., Diab, S. G., Canil, C., McWilliam, M., Thall, A., Ruiz-Garcia, A., Zhang, K., Tye, L., Chao, R. C., Camidge, D. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286593/
https://www.ncbi.nlm.nih.gov/pubmed/21989766
http://dx.doi.org/10.1007/s00280-011-1755-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286593/
https://www.ncbi.nlm.nih.gov/pubmed/21989766
http://dx.doi.org/10.1007/s00280-011-1755-0

Ejemplares similares